Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P35858
UPID:
ALS_HUMAN
Alternative names:
-
Alternative UPACC:
P35858; B4DZY8; E9PGU3
Background:
The Insulin-like growth factor-binding protein complex acid labile subunit plays a pivotal role in mediating protein-protein interactions, leading to the formation of protein complexes, receptor-ligand binding, and cell adhesion. This protein is essential for the regulation of growth and development.
Therapeutic significance:
Acid-labile subunit deficiency, a condition marked by significantly reduced serum IGF-I and IGFBP-3 concentrations alongside mild growth retardation, is directly linked to mutations in the gene encoding this protein. Understanding its role could pave the way for innovative treatments targeting growth disorders.